pubmed.ncbi.nlm.nih.gov

The effectiveness of quick starting oral contraception containing nomegestrol acetate and 17-β estradiol on ovulation inhibition: A randomized controlled trial - PubMed

  • ️Wed Jan 01 2020

Randomized Controlled Trial

The effectiveness of quick starting oral contraception containing nomegestrol acetate and 17-β estradiol on ovulation inhibition: A randomized controlled trial

Preeyaporn Jirakittidul et al. Sci Rep. 2020.

Abstract

To determine the effectiveness of quick starting combined oral contraception (COC) contain 2.5 mg nomegestrol acetate and 1.5 mg estradiol (NOMAC/E2) comparing with 0.075 mg gestodene and 0.02 mg ethinyl estradiol (GS/EE) on ovarian ovulation inhibition rate, we conducted a non-inferiority randomized controlled trial involving 69 healthy female volunteers aged 18-40 years who had normal menstrual history and were randomized at a 2:1 ratio to take one pack of COC containing either NOMAC/E2 (study group) or GS/EE (control group) starting on menstrual cycle Day7-9. The ovarian activity was assessed by using Hoogland and Skouby grading. Forty-six and 23 participants were randomized to NOMAC/E2 and GS/EE groups, respectively. Baseline characteristics were similar between groups. No significant difference was observed between the study and control groups for ovulation inhibition rate (93.4% vs. 95.6%, risk difference: -2.2%, 95% CI: -13.1, 8.8), ovarian quiescence rate (91.2% vs. 91.2%, P = 1.000), persistent cyst rate (2.2% vs. 4.4%, P = 1.000), and ovulation rate (6.6% vs. 4.4%, P = 1.000). Quick starting COC during day7-9 of menstrual cycle can inhibit ovulation for more than 90%. The quick starting NOMAC/E2 is non-inferior to GS/EE for preventing ovulation and suppressing follicular growth.

PubMed Disclaimer

Conflict of interest statement

All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drugs, devices, or materials described in this report.

Figures

Figure 1
Figure 1

Consort flow chart. Abbreviations: *, missed taking pills more than 24 hours apart; GST/EE, 0.075 mg gestodene plus 0.02 mg ethinyl estradiol; NOMAC/E2, 2.5 mg nomegestrol acetate plus 1.5 mg estradiol.

Figure 2
Figure 2

Kaplan-Meier survival curve of per protocol population illustrates cumulative incidence of ovulation inhibition of quick starting combined oral contraception. Abbreviations: Day0, day of starting COC; Day 28, day of finishing COC package; GST/EE, 0.075 mg gestodene plus 0.02 mg ethinyl estradiol; NOMAC/E2, 2.5 mg nomegestrol acetate plus 1.5 mg estradiol.

Similar articles

Cited by

References

    1. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best. Pract. Res. Clin. Endocrinol. Metab. 2013;27:3–12. doi: 10.1016/j.beem.2012.11.004. - DOI - PubMed
    1. D’Arpe S, et al. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. Reprod. Biomed. Online. 2016;33:436–48. doi: 10.1016/j.rbmo.2016.07.010. - DOI - PubMed
    1. Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Dusterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 2011;84:549–57. doi: 10.1016/j.contraception.2011.04.009. - DOI - PubMed
    1. Morroni C, Findley M, Westhoff C. Does using the “pregnancy checklist” delay safe initiation of contraception? Contraception. 2017;95:331–4. doi: 10.1016/j.contraception.2017.01.006. - DOI - PubMed
    1. Curtis KM, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm. Rep. 65 No. RR- 2016;4:1–66. doi: 10.15585/mmwr.rr6504a1. - DOI - PubMed

Publication types

MeSH terms

Substances